Compare Global X Copper Miners ETF (COPX) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Heron Therapeutics Inc — how do they compare? Global X Copper Miners ETF trades at $84.47 (market cap $7.10B), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: Global X Copper Miners ETF is far larger — about 104.4× Heron Therapeutics Inc's market cap, and Global X Copper Miners ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Heron Therapeutics Inc for 35 Days on average.
| COPX | HRTX | |
|---|---|---|
Market Cap | $7.10B | $68.01M |
Volume | 2,871,128 | 1,891,941 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $1.49 |
52-Week Low | $57.43 | $0.27 |
Typical Hold Time | 50 Days | 35 Days |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) is trading at $83.58, down 3.13% with a bearish technical signal. The ETF faces selling pressure with 15 sell signals versus 2 buy signals across technical indicators. Copper fundamentals remain strong with prices near all-time highs above $6.85 per pound, driven by AI infrastructure demand and supply constraints. Recent news highlights copper's critical role in electrification and AI infrastructure, though technical indicators suggest near-term weakness.
The long-term copper thesis remains compelling due to structural supply deficits and AI-driven demand growth. However, near-term risks include potential Federal Reserve policy impacts and mining equity underperformance relative to copper prices. The ETF offers operational leverage to copper prices but faces volatility from global surplus projections and macroeconomic factors.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
